Hypofractionated radiotherapy plus PD-1 antibody and SOX chemotherapy as second-line therapy in metastatic pancreatic cancer: a single-arm, phase II clinical trial.

MLA

Wang, Qin, et al. “Hypofractionated Radiotherapy plus PD-1 Antibody and SOX Chemotherapy as Second-Line Therapy in Metastatic Pancreatic Cancer: A Single-Arm, Phase II Clinical Trial.” Cancer Immunology, Immunotherapy : CII, vol. 73, no. 10, Aug. 2024, p. 201. EBSCOhost, https://doi.org/10.1007/s00262-024-03744-z.

APA

Wang, Q., Tong, F., Qiao, L., Qi, L., Sun, Y., Zhu, Y., Ni, J., Liu, J., Kong, W., Liu, B., & Du, J. (2024). Hypofractionated radiotherapy plus PD-1 antibody and SOX chemotherapy as second-line therapy in metastatic pancreatic cancer: a single-arm, phase II clinical trial. Cancer Immunology, Immunotherapy : CII, 73(10), 201. https://doi.org/10.1007/s00262-024-03744-z

Chicago

Wang, Qin, Fan Tong, Li Qiao, Liang Qi, Yi Sun, Yahui Zhu, Jiayao Ni, et al. 2024. “Hypofractionated Radiotherapy plus PD-1 Antibody and SOX Chemotherapy as Second-Line Therapy in Metastatic Pancreatic Cancer: A Single-Arm, Phase II Clinical Trial.” Cancer Immunology, Immunotherapy : CII 73 (10): 201. doi:10.1007/s00262-024-03744-z.